UPS (NYSE:UPS), a global leader in logistics, today announced thatit is working with QIAGEN, a leading global provider of moleculardiagnostics and sample preparation technologies, to deliver nucleicacid extraction kits critical to COVID-19 testing, as well as itsnovel QIAstat-Dx Coronavirus testing cartridges to destinationsaround the world. With governments and public authoritiesclassifying UPS as an essential service provider, the company iscombining the flexibility of its global network with QIAGEN’sincreased production capacity for COVID-19 testing kits produced attheir facility in Hilden, Germany to help healthcare workers curbthe spread of the disease.
“Customers and governments around the world are turning to thereliability of UPS’s smart global logistics network to help fightthis pandemic,” said Lou Rivieccio, president, UPS Europe.“Business continuity has never been more important for ourcustomers and that is what we continue to deliver whether it be fordelivery or storage of medicines, testing kits or medical supplies.And when it comes to ensuring that increased production volumes oftesting kits reach vital destinations around the world such ashospitals and labs, our teams are here to help customers navigatecomplexity and focus on fighting this pandemic. Agility,flexibility and fast response in the supply chain arena are helpingto combat this outbreak as it shifts from Asia to Europe and NorthAmerica.”
